---
title: "ABACHEM: The company's chlorantraniliprole intermediate products adopt a CDMO model and do not participate in market competition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244531038.md"
description: "ABACHEM stated in an institutional research that its subsidiary Nantong ABACHEM Co., Ltd. produces the chlorantraniliprole intermediate K acid using the CDMO model, with an annual production capacity of 2,000 tons. This product is currently supplied exclusively to a single customer and is not involved in market sales. The cooperation agreement with the customer is being renewed and a new agreement has not yet been formally signed. This model has not had a negative impact on the company's business, and future order changes need to be negotiated with the customer"
datetime: "2025-06-14T03:53:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244531038.md)
  - [en](https://longbridge.com/en/news/244531038.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244531038.md)
generator: "portal-rs"
---

# ABACHEM: The company's chlorantraniliprole intermediate products adopt a CDMO model and do not participate in market competition

ABACHEM stated during an institutional research that its subsidiary Nantong ABACHEM Co., Ltd. has an annual production capacity of 2,000 tons of the chlorantraniliprole intermediate K acid, using a CDMO business model to provide customized production and delivery based on customer orders. Currently, the company supplies this product exclusively to a single customer and does not sell it on the market. The relevant business is still operating normally, continuously supplying the customer. Regarding the renewal of the cooperation agreement, the company has received the customer's intention to extend. Due to adjustments in the market supply and demand pattern and customer strategies after the expiration of downstream product patents, both parties still need to further discuss the agreement terms, and a new agreement has not yet been formally signed. The signing of the new cooperation agreement will require both parties to jointly promote and reach a consensus. The company's chlorantraniliprole intermediate product adopts a CDMO model and does not participate in market competition. So far, this incident has not had a negative impact on the company's business. Given that the company supplies this product to a single customer, any changes in orders still need to be specifically negotiated with the customer, and it is currently impossible to predict the impact on the company's business and performance

### Related Stocks

- [300261.CN](https://longbridge.com/en/quote/300261.CN.md)

## Related News & Research

- ["July Was A Bad Month": Jane Street Lost $15 Billion In First Down Month In A Decade](https://longbridge.com/en/news/296131995.md)
- [11:06 ETEndurance Named to Inc. 5000 for 11th Time, Continuing National Growth](https://longbridge.com/en/news/296124358.md)
- [Panoro Energy places USD 50 million senior unsecured bond offering](https://longbridge.com/en/news/296383048.md)
- [REG - Cloudcoco Group PLC - Director/PDMR Shareholding](https://longbridge.com/en/news/296131812.md)
- [GRAINS-Soybeans near three-week high on China demand, crop worries](https://longbridge.com/en/news/296295616.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**